Elevate Capital Advisors LLC Has $919,000 Position in Chemed Corporation $CHE

Elevate Capital Advisors LLC lowered its stake in shares of Chemed Corporation (NYSE:CHE) by 14.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,887 shares of the company’s stock after selling 311 shares during the period. Elevate Capital Advisors LLC’s holdings in Chemed were worth $919,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. Alpine Bank Wealth Management acquired a new stake in shares of Chemed in the 1st quarter valued at $29,000. HM Payson & Co. bought a new position in Chemed in the 1st quarter worth $30,000. SVB Wealth LLC bought a new position in Chemed in the 1st quarter worth $30,000. WPG Advisers LLC bought a new position in shares of Chemed during the 1st quarter worth about $32,000. Finally, Geneos Wealth Management Inc. increased its holdings in shares of Chemed by 330.4% during the 1st quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock worth $61,000 after purchasing an additional 76 shares during the period. Institutional investors and hedge funds own 95.85% of the company’s stock.

Insider Activity at Chemed

In other news, EVP Nicholas Michael Westfall sold 10,012 shares of the company’s stock in a transaction that occurred on Monday, August 4th. The shares were sold at an average price of $421.91, for a total transaction of $4,224,162.92. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director George J. Walsh III bought 200 shares of Chemed stock in a transaction dated Monday, August 4th. The shares were bought at an average price of $417.10 per share, for a total transaction of $83,420.00. Following the completion of the transaction, the director directly owned 3,523 shares of the company’s stock, valued at $1,469,443.30. This represents a 6.02% increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 13,162 shares of company stock valued at $5,677,511 over the last ninety days. Company insiders own 3.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on CHE shares. Jefferies Financial Group upgraded shares of Chemed from a “hold” rating to a “buy” rating and lifted their target price for the company from $490.00 to $550.00 in a research report on Tuesday, September 2nd. Oppenheimer decreased their target price on shares of Chemed from $650.00 to $580.00 and set an “outperform” rating on the stock in a research report on Thursday, July 31st. Bank of America decreased their target price on shares of Chemed from $610.00 to $595.00 and set a “buy” rating on the stock in a research report on Wednesday, September 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Chemed in a research report on Saturday, September 27th. Finally, Royal Bank Of Canada decreased their target price on shares of Chemed from $640.00 to $589.00 and set an “outperform” rating on the stock in a research report on Thursday, July 31st. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $578.50.

Chemed Trading Up 0.2%

Shares of Chemed stock opened at $442.75 on Friday. The stock has a market capitalization of $6.45 billion, a price-to-earnings ratio of 22.76, a P/E/G ratio of 2.57 and a beta of 0.43. Chemed Corporation has a 1-year low of $408.42 and a 1-year high of $623.60. The firm’s 50-day moving average price is $448.71 and its two-hundred day moving average price is $516.41.

Chemed (NYSE:CHE) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $4.27 earnings per share for the quarter, missing the consensus estimate of $6.02 by ($1.75). The firm had revenue of $618.80 million for the quarter, compared to the consensus estimate of $650.60 million. Chemed had a return on equity of 25.83% and a net margin of 11.56%.Chemed’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same period in the prior year, the company posted $5.47 earnings per share. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. As a group, equities research analysts predict that Chemed Corporation will post 21.43 EPS for the current year.

Chemed Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, August 29th. Stockholders of record on Monday, August 11th were given a dividend of $0.60 per share. The ex-dividend date was Monday, August 11th. This is a positive change from Chemed’s previous quarterly dividend of $0.50. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.5%. Chemed’s dividend payout ratio (DPR) is currently 12.34%.

Chemed Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.